<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03909165</url>
  </required_header>
  <id_info>
    <org_study_id>8616-169</org_study_id>
    <secondary_id>2017-000693-11</secondary_id>
    <secondary_id>MK-8616-169</secondary_id>
    <nct_id>NCT03909165</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to &lt;2 Years (MK-8616-169)</brief_title>
  <official_title>A Phase 4 Double-blinded, Randomized, Active Comparator-controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to &lt;2 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy, safety, and pharmacokinetics (PK) of sugammadex&#xD;
      (MK-8616) for reversal of both moderate and deep neuromuscular blockade (NMB) in pediatric&#xD;
      participants aged birth to &lt;2 years. The primary hypothesis of this study is that sugammadex&#xD;
      is superior to neostigmine in reversing moderate NMB as measured by time to neuromuscular&#xD;
      recovery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial will be conducted in two parts: Part A and Part B. In Part A, PK sampling will be&#xD;
      conducted to identify the pediatric dose providing sugammadex exposure comparable to the next&#xD;
      oldest age cohort. For Part B participants, the efficacy of sugammadex (i.e. neuromuscular&#xD;
      recovery / time to extubation) will be assessed. Further, safety analyses will be conducted&#xD;
      in both Parts A and B. Following completion of Part A, an interim analysis (IA) of the PK and&#xD;
      safety data will be performed. Once the appropriate doses are confirmed and safety data is&#xD;
      assessed for the 2 doses of sugammadex, then Part B will commence.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 23, 2019</start_date>
  <completion_date type="Anticipated">March 23, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 23, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Part A will be open-label, while Part B will be double-blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Part A. Area Under the Plasma Concentration Time Curve (AUC) for Sugammadex</measure>
    <time_frame>Baseline and 2, 15, 30, 60, 240 to 360, and 600 to 720 minutes post-dose</time_frame>
    <description>The AUC for sugammadex in plasma will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A. Plasma Clearance (CL) of Sugammadex</measure>
    <time_frame>Baseline and 2, 15, 30, 60, 240 to 360, and 600 to 720 minutes post-dose</time_frame>
    <description>The CL for sugammadex will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A. Apparent Volume of Distribution (Vz) for Sugammadex</measure>
    <time_frame>Baseline and 2, 15, 30, 60, 240 to 360, and 600 to 720 minutes post-dose</time_frame>
    <description>The Vz for sugammadex will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A. Apparent Volume of Distribution at Steady State (Vss) for Sugammadex</measure>
    <time_frame>Baseline and 2, 15, 30, 60, 240 to 360, and 600 to 720 minutes post-dose</time_frame>
    <description>The Vss for sugammadex will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A. Maximum Plasma Concentration (Cmax) of Sugammadex</measure>
    <time_frame>Baseline and 2, 15, 30, 60, 240 to 360, and 600 to 720 minutes post-dose</time_frame>
    <description>The Cmax for sugammadex will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A. Half-Life (t1/2) of Sugammadex in Plasma</measure>
    <time_frame>Baseline and 2, 15, 30, 60, 240 to 360, and 600 to 720 minutes post-dose</time_frame>
    <description>The t1/2 for sugammadex will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B. Time to Neuromuscular Recovery</measure>
    <time_frame>Within Day 1</time_frame>
    <description>Time to neuromuscular recovery will be reported, defined as the interval from administration of reversal agent to time to neuromuscular recovery.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts A and B. Adverse Events (AEs)</measure>
    <time_frame>Up to 7 days</time_frame>
    <description>The number of participants experiencing an AE will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part B. Time to Extubation</measure>
    <time_frame>Within Day 1</time_frame>
    <description>Time to extubation will be reported, defined as the interval from administration of reversal agent to removal of the endotracheal tube.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Neuromuscular Blockade</condition>
  <arm_group>
    <arm_group_label>Part A. Sugammadex 2 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous (IV) bolus of sugammadex at 2 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A. Sugammadex 4 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV bolus of sugammadex at 4 mg/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B. Sugammadex 2 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV bolus of sugammadex at 2 mg/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B. Sugammadex 4 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV bolus of sugammadex at 4 mg/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B. Neostigmine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single IV bolus containing neostigmine (50 μg/kg; up to 5 mg maximum dose) in combination with either glycopyrrolate (10 μg/kg) or atropine sulfate (20 μg/kg).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex 2 mg/kg</intervention_name>
    <description>For moderate NMB reversal, a single IV bolus of sugammadex (2 mg/kg) will be given after final dose of neuromuscular blocking agent (NMBA; rocuronium or vecuronium) and within 2 minutes of the reappearance of a second twitch (T2) in response to train-of-four (TOF) stimulations.</description>
    <arm_group_label>Part A. Sugammadex 2 mg/kg</arm_group_label>
    <arm_group_label>Part B. Sugammadex 2 mg/kg</arm_group_label>
    <other_name>MK-8616</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex 4 mg/kg</intervention_name>
    <description>For deep NMB reversal, a single IV bolus of sugammadex (4 mg/kg) will be given after final dose of NMBA (rocuronium or vecuronium) and within 2 minutes of detection of a target of 1 to 2 post-tetanic counts and no response to TOF stimulations (TOF=0).</description>
    <arm_group_label>Part A. Sugammadex 4 mg/kg</arm_group_label>
    <arm_group_label>Part B. Sugammadex 4 mg/kg</arm_group_label>
    <other_name>MK-8616</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neostigmine + Glycopyrrolate</intervention_name>
    <description>For moderate NMB reversal, a single i.v. bolus containing both neostigmine (50 μg/kg; up to 5 mg maximum dose) as well as glycopyrrolate (10 μg/kg) will be given after final dose of NMBA (rocuronium or vecuronium) and within 2 minutes of the reappearance of T2 in response to TOF stimulations.</description>
    <arm_group_label>Part B. Neostigmine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neostigmine + Atropine</intervention_name>
    <description>For moderate NMB reversal, a single i.v. bolus containing both neostigmine (50 μg/kg; up to 5 mg maximum dose) as well as atropine (20 μg/kg) will be given after final dose of NMBA (rocuronium or vecuronium) and within 2 minutes of the reappearance of T2 in response to TOF stimulations.</description>
    <arm_group_label>Part B. Neostigmine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Categorized as American Society of Anesthesiologists (ASA) Physical Status Class 1, 2,&#xD;
             or 3.&#xD;
&#xD;
          -  Has a planned non-emergent surgical procedure or clinical situation (e.g., intubation)&#xD;
             that requires moderate or deep NMB with either rocuronium or vecuronium.&#xD;
&#xD;
          -  Has a surgical procedure or clinical situation that would allow neuromuscular&#xD;
             monitoring techniques to be applied for neuromuscular transmission monitoring.&#xD;
&#xD;
          -  Is male or female, between birth and &lt;2 years of age.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Is a preterm infant or neonate &lt;36 weeks gestational age at birth.&#xD;
&#xD;
          -  Has any clinically significant condition or situation (e.g., anatomical malformation&#xD;
             that complicates intubation) other than the condition requiring the use of NMBA that,&#xD;
             in the opinion of the investigator, would interfere with the trial evaluations or&#xD;
             optimal participation in the trial.&#xD;
&#xD;
          -  Has a neuromuscular disorder that may affect NMB and/or trial assessments.&#xD;
&#xD;
          -  Is dialysis-dependent or has (or is suspected of having) severe renal insufficiency.&#xD;
&#xD;
          -  Has or is suspected of having a family or personal history of malignant hyperthermia.&#xD;
&#xD;
          -  Has or is suspected of having an allergy to study treatments or its/their excipients,&#xD;
             to opioids/opiates, muscle relaxants or their excipients, or other medication(s) used&#xD;
             during general anesthesia.&#xD;
&#xD;
          -  Is expected to require mechanical ventilation after the procedure.&#xD;
&#xD;
          -  Has received or is planned to receive toremifene and/or fusidic acid via IV&#xD;
             administration within 24 hours before or within 24 hours after administration of study&#xD;
             treatment.&#xD;
&#xD;
          -  Use of medication expected to interfere with study treatments given in this trial.&#xD;
&#xD;
          -  Has been previously treated with sugammadex or has participated in a sugammadex&#xD;
             clinical trial within 30 days of signing the informed consent form of this current&#xD;
             trial.&#xD;
&#xD;
          -  Is currently participating in or has participated in an interventional clinical trial&#xD;
             with an investigational compound or device within 30 days of signing the informed&#xD;
             consent/assent for this current trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>2 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lucille Packard Children's Hospital ( Site 3008)</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>650-724-2320</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Variety Children's Hospital D.B.A. Nicklaus Children's Hospital ( Site 3019)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>786-624-2853</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>OU Medical Center ( Site 3005)</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia ( Site 3021)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>267-426-0897</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh UPMC ( Site 3017)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>412-692-5585</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>McGovern Medical School at UT Health/ Memorial Hermann ( Site 3014)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>713-500-5075</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Vermont Medical Center ( Site 3013)</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>The Children s Hospital at Westmead ( Site 3805)</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61731766577</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queensland Children s Hospital ( Site 3806)</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61730681111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Childrens Hospital Melbourne ( Site 3801)</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61399366086</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaire Ziekenhuis Antwerpen - UZA ( Site 3200)</name>
      <address>
        <city>Edegem</city>
        <state>Antwerpen</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3238214788</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Brussel ( Site 3201)</name>
      <address>
        <city>Brussels</city>
        <state>Bruxelles-Capitale, Region De</state>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3224778962</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Leuven - Campus Gasthuisberg ( Site 3202)</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams-Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3216341374</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Pequeno Principe ( Site 3826)</name>
      <address>
        <city>Curitiba</city>
        <state>Parana</state>
        <zip>80250-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5541999946175</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Tacchini ( Site 3827)</name>
      <address>
        <city>Bento Goncalves</city>
        <state>Rio Grande Do Sul</state>
        <zip>95700-084</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+555434554333</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto da Crianca do Hospital das Clinicas-FMUSP ( Site 3825)</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05403-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5511999116677</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet ( Site 3250)</name>
      <address>
        <city>Copenhagen</city>
        <state>Hovedstaden</state>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+45 35453545</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>New Childrens Hospital ( Site 3750)</name>
      <address>
        <city>Helsinki</city>
        <state>Uusimaa</state>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+358504271382</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>C.H.R.U. de Lille. Hopital Jeanne de Flandres ( Site 3304)</name>
      <address>
        <city>Lille</city>
        <state>Nord</state>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33320446269</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unidad de Cirugía Cardiovascular ( Site 4126)</name>
      <address>
        <city>Guatemala</city>
        <zip>01011</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+50224163000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szegedi Tudomanyegyetem ( Site 4201)</name>
      <address>
        <city>Szeged</city>
        <state>Csongrad</state>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3662545331</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Klinikai Kozpont ( Site 4200)</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3652411600/54701</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarawak General Hospital ( Site 3877)</name>
      <address>
        <city>Kuching</city>
        <state>Sarawak</state>
        <zip>93586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+60128862863</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Women and Children Hospital Kuala Lumpur (Hospital Tunku Azizah) ( Site 3875)</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50300</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+60326155555</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Malaya Medical Centre. ( Site 3876)</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+60379494422</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General de Zona No. 1 ( Site 4153)</name>
      <address>
        <city>Villa De Alvarez</city>
        <state>Colima</state>
        <zip>28984</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+523123146199</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centenario Hospital Miguel Hidalgo-Pediatrics Department ( Site 4152)</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20259</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5214494489875</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Center ( Site 4226)</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+31243614553</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus University Medical Center ( Site 4225)</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+31107037379</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen ( Site 4227)</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+31503615519</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wilhelmina Kinderziekenhuis ( Site 4228)</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 EA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+31887555555</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional Cardiovascular Incor ( Site 3928)</name>
      <address>
        <city>Lima</city>
        <zip>15072</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5112657113</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Scientific Research Institute Complex Problems Cardiovascular Disease ( Site 4288)</name>
      <address>
        <city>Kemerovo</city>
        <state>Kemerovskaya Oblast</state>
        <zip>650002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79039082770</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>NMRC Obstetrics Gynecology and Perinatology n.a. V.I. Kulakov ( Site 4287)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>117997</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79104716934</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pediatric Hematology Oncology and Immunology Centre n.a. D.Rogachev. ( Site 4275)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>117997</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+74952876570</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children City Clinical Hospital 13 n.a N.F.Filatov ( Site 4285)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>123001</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79162366627</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children City Clinical Hospital #9 n.a. G.N.Speransky ( Site 4290)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>123317</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Scientific-Research Clinical Pediatric Institution n.a. Veltischev ( Site 4276)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>125412</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+74954833485</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St.Petersburg State Pediatric Medical University ( Site 4281)</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>194100</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79217400620</phone>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Guatemala</country>
    <country>Hungary</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Peru</country>
    <country>Russian Federation</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 8, 2019</study_first_submitted>
  <study_first_submitted_qc>April 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2019</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atropine</mesh_term>
    <mesh_term>Glycopyrrolate</mesh_term>
    <mesh_term>Neostigmine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

